Overview Dividends

(SLNO) Soleno Therapeutics - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US8342033094

Diazoxide, Choline, Tablet, Rare, Disease

EPS (Earnings per Share)

EPS (Earnings per Share) of SLNO over the last years for every Quarter: "2020-09": -1.65, "2020-12": -0.6, "2021-03": -1.65, "2021-06": -2.1, "2021-09": -1.5, "2021-12": -0.6, "2022-03": -1.08, "2022-06": -0.9, "2022-09": -0.76, "2022-12": -0.58, "2023-03": -0.88, "2023-06": -0.81, "2023-09": -0.95, "2023-12": -0.33, "2024-03": -0.59, "2024-06": -0.57, "2024-09": -1.83, "2024-12": -1.27, "2025-03": -0.95, "2025-06": -0.09, "2025-09": 0.47,
EPS Growth (3y CAGR): 23.72%
EPS Trend (3y Corr): 33.5%
Last SUE: 0.85σ
Qual. Beats: 2

Revenue

Revenue of SLNO over the last years for every Quarter: 2020-09: 0, 2020-12: 0, 2021-03: 0, 2021-06: 0, 2021-09: 0, 2021-12: 0, 2022-03: 0, 2022-06: 0, 2022-09: 0, 2022-12: 0, 2023-03: 0, 2023-06: 0, 2023-09: 0, 2023-12: 3.446, 2024-03: 0, 2024-06: 0, 2024-09: 0, 2024-12: 0, 2025-03: 0, 2025-06: 32.657, 2025-09: 66.018,
Revenue Growth (3y CAGR): 139.16%
Revenue Trend (3y Corr): 60.4%
Last SUE: 4.00σ
Qual. Beats: 2
Risk via 10d forecast
Volatility 77.1%
Value at Risk 5%th 104%
Relative Tail Risk -17.62%
Reward TTM
Sharpe Ratio 0.11
Alpha -23.73
Character TTM
Hurst Exponent 0.409
Beta 0.812
Beta Downside 1.053
Drawdowns 3y
Max DD 50.80%
Mean DD 13.80%
Median DD 13.79%

Description: SLNO Soleno Therapeutics November 05, 2025

Soleno Therapeutics, Inc. (NASDAQ: SLNO) is a clinical-stage biopharma focused on rare-disease therapeutics. Its flagship candidate, Diazoxide Choline Extended-Release (DCE-R) tablets, is a once-daily oral formulation currently in a Phase III trial for Prader-Willi Syndrome (PWS), a genetically-defined neurodevelopmental disorder with an estimated U.S. prevalence of ~1 in 15,000.

As of the most recent 10-Q (Q2 2024), Soleno reported cash and cash equivalents of roughly **$55 million**, giving it an estimated 12-month runway at current burn (~$4-5 million per month). The Phase III trial is slated to complete enrollment by Q4 2024, with topline data expected in H1 2025. If successful, the U.S. orphan-drug market for PWS is projected to exceed **$250 million** annually, driven by limited competition and premium pricing under the Orphan Drug Act.

Sector-wide, rare-disease biotech firms have benefited from a **15 % CAGR** in orphan-drug sales over the past five years, supported by higher reimbursement rates, accelerated FDA pathways, and a robust pipeline of gene-therapy entrants that raise overall investor appetite for niche indications. However, Soleno’s valuation remains highly sensitive to Phase III outcomes and the ability to secure a partnership or commercialization partner, given its limited sales infrastructure.

For a deeper, data-driven look at Soleno’s risk-adjusted upside and comparable peer metrics, you may find the analyst tools on ValueRay useful for extending your due-diligence.

SLNO Stock Overview

Market Cap in USD 2,543m
Sub-Industry Biotechnology
IPO / Inception 2014-11-13
Return 12m vs S&P 500 -26.7%
Analyst Rating 4.63 of 5

SLNO Dividends

Currently no dividends paid

SLNO Growth Ratios

Metric Value
CAGR 3y 250.60%
CAGR/Max DD Calmar Ratio 4.93
CAGR/Mean DD Pain Ratio 18.16
Current Volume 1530.6k
Average Volume 1606.7k

Piotroski VR‑10 (Strict, 0-10) 1.0

Net Income (-78.5m TTM) > 0 and > 6% of Revenue (6% = 5.92m TTM)
FCFTA -0.04 (>2.0%) and ΔFCFTA 13.11pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)
NWC/Revenue 508.3% (prev 7059 %; Δ -6550 pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)
CFO/TA -0.04 (>3.0%) and CFO -25.7m > Net Income -78.5m (YES >=105%, WARN >=100%)
NO Net Debt/EBITDA fails (EBITDA <= 0)
Current Ratio 16.08 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)
Outstanding Shares last Quarter (54.9m) change vs 12m ago 31.14% (target <= -2.0% for YES)
Gross Margin 98.14% (prev 57.25%; Δ 40.88pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)
Asset Turnover 22.01% (prev 1.16%; Δ 20.85pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)
Interest Coverage Ratio -15.68 (EBITDA TTM -66.3m / Interest Expense TTM 4.36m) >= 6 (WARN >= 3)

Altman Z'' -2.86

(A) 0.84 = (Total Current Assets 534.9m - Total Current Liabilities 33.3m) / Total Assets 599.9m
(B) -0.79 = Retained Earnings (Balance) -474.7m / Total Assets 599.9m
(C) -0.15 = EBIT TTM -68.3m / Avg Total Assets 448.3m
(D) -4.51 = Book Value of Equity -474.3m / Total Liabilities 105.1m
Total Rating: -2.86 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 41.66

1. Piotroski 1.0pt
2. FCF Yield -1.26%
3. FCF Margin -26.09%
4. Debt/Equity 0.01
5. Debt/Ebitda 3.68
7. RoE -25.88%
8. Rev. Trend 60.40%
9. EPS Trend 33.50%

What is the price of SLNO shares?

As of November 21, 2025, the stock is trading at USD 44.95 with a total of 1,530,590 shares traded.
Over the past week, the price has changed by -5.07%, over one month by -31.32%, over three months by -34.80% and over the past year by -18.02%.

Is SLNO a buy, sell or hold?

Soleno Therapeutics has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy SLNO.
  • Strong Buy: 5
  • Buy: 3
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0

What are the forecasts/targets for the SLNO price?

Issuer Target Up/Down from current
Wallstreet Target Price 116.8 159.7%
Analysts Target Price 116.8 159.7%
ValueRay Target Price 51.1 13.7%

SLNO Fundamental Data Overview November 15, 2025

Market Cap USD = 2.54b (2.54b USD * 1.0 USD.USD)
P/E Forward = 9.8522
P/S = 25.7732
P/B = 5.1821
Beta = -3.187
Revenue TTM = 98.7m USD
EBIT TTM = -68.3m USD
EBITDA TTM = -66.3m USD
Long Term Debt = 49.9m USD (from longTermDebt, last quarter)
Short Term Debt = 697.0k USD (from shortTermDebt, last quarter)
Debt = 2.81m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -243.9m USD (from netDebt column, last quarter)
Enterprise Value = 2.05b USD (2.54b + Debt 2.81m - CCE 498.9m)
Interest Coverage Ratio = -15.68 (Ebit TTM -68.3m / Interest Expense TTM 4.36m)
FCF Yield = -1.26% (FCF TTM -25.7m / Enterprise Value 2.05b)
FCF Margin = -26.09% (FCF TTM -25.7m / Revenue TTM 98.7m)
Net Margin = -79.50% (Net Income TTM -78.5m / Revenue TTM 98.7m)
Gross Margin = 98.14% ((Revenue TTM 98.7m - Cost of Revenue TTM 1.84m) / Revenue TTM)
Gross Margin QoQ = 98.27% (prev 97.87%)
Tobins Q-Ratio = 3.41 (Enterprise Value 2.05b / Total Assets 599.9m)
Interest Expense / Debt = 49.48% (Interest Expense 1.39m / Debt 2.81m)
Taxrate = 100.0% (out of range, set to none) (-175.8m / -175.8m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 16.08 (Total Current Assets 534.9m / Total Current Liabilities 33.3m)
Debt / Equity = 0.01 (Debt 2.81m / totalStockholderEquity, last quarter 494.8m)
Debt / EBITDA = 3.68 (negative EBITDA) (Net Debt -243.9m / EBITDA -66.3m)
Debt / FCF = 9.47 (negative FCF - burning cash) (Net Debt -243.9m / FCF TTM -25.7m)
Total Stockholder Equity = 303.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -13.08% (Net Income -78.5m / Total Assets 599.9m)
RoE = -25.88% (Net Income TTM -78.5m / Total Stockholder Equity 303.1m)
RoCE = -19.36% (EBIT -68.3m / Capital Employed (Equity 303.1m + L.T.Debt 49.9m))
RoIC = -100.9% (out of range, set to none) (EBIT -68.3m / (Assets 599.9m - Curr.Liab 33.3m - Cash 498.9m))
WACC = 9.00% (E(2.54b)/V(2.55b) * Re(9.01%) + (debt cost/tax rate unavailable))
Discount Rate = 9.01% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 44.37%
Fair Price DCF = unknown (Cash Flow -25.7m)
EPS Correlation: 33.50 | EPS CAGR: 23.72% | SUE: 0.85 | # QB: 2
Revenue Correlation: 60.40 | Revenue CAGR: 139.2% | SUE: 4.0 | # QB: 2

Additional Sources for SLNO Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle